China
Africa
Explore chapters and articles related to this topic
Viral Infections
Published in Ayşe Serap Karadağ, Lawrence Charles Parish, Jordan V. Wang, Roxburgh's Common Skin Diseases, 2022
Management: Erythema infectiosum is generally self-resolving, and there is no specific anti-viral therapy for Parvovirus B19. Therapy is supportive. If patients are experiencing arthralgias, then nonsteroidal anti-inflammatory drugs can be used. Patients with aplastic crises may need red blood cell transfusions depending on anemia severity. For pregnant women, fetal ultrasonography and monitoring are recommended.
Answers
Published in Kristen Davies, Shadaba Ahmed, Core Conditions for Medical and Surgical Finals, 2020
Treatment options include simple analgesia and NSAIDs for joint pain; DMARDs, anti-TNFs and biologics can now be utilised to help manage both the arthralgia and skin disease. Specific medications include apremilast, secukinumab and ixekizumab.
The Measurement of Acute Phase Proteins as Disease Markers
Published in Andrzej Mackiewicz, Irving Kushner, Heinz Baumann, Acute Phase Proteins, 2020
John T. Whicher, Rosamonde E. Banks, Douglas Thompson, Stuart W. Evans
Arthralgia is a common nonspecific symptom which can be caused by a variety of local, systemic, and psychogenic factors. The finding of elevated acute phase proteins may confirm organic disease. Similarly, back pain is usually nonspecific. The presence of an acute phase response can give a strong indication of organic disease such as ankylosing spondylitis or cancer. In ankylosing spondylitis, serum CRP may be elevated before the diagnosis is clinically obvious,120 although there is currently no consensus about the relationship of CRP or the ESR to disease activity.
Temporomandibular disorders and neck pain in primary headache patients: a retrospective machine learning study
Published in Acta Odontologica Scandinavica, 2023
Martina Ferrillo, Mario Migliario, Nicola Marotta, Francesco Fortunato, Marino Bindi, Federica Pezzotti, Antonio Ammendolia, Amerigo Giudice, Pier Luigi Foglio Bonda, Alessandro de Sire
The diagnosis of TMD involves Axis I for the clinical examination and Axis II for the pain-related disability. Thus, Axis I classifies TMD into three groups:Group I. Muscle diagnoses: (a) myofascial pain; (b) myofascial pain with limited openingGroup II. Disc displacements: (a) disc displacement with reduction; (b) disc displacement without reduction, with limited opening; (c) disc displacement without reduction, without limited opening.Group III. Arthralgia, osteoarthritis, osteoarthrosis: (a) arthralgia; (b) osteoarthritis of the temporomandibular joint; (c) osteoarthrosis of the temporomandibular joint.
Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study
Published in Journal of Asthma, 2022
Ana Isabel Enríquez-Rodríguez, Tamara Hermida Valverde, Pedro Romero Álvarez, Francisco Julián López-González, Jose Antonio Gullón Blanco, Ana Rosa Expósito Villegas, María José Escobar Fernández, Ana María Beristáin Urquiza, Miguel Ángel Alonso Fernández, Margarita Gutiérrez Rodríguez, Gema Castaño De las Pozas, Jennifer Jiménez Pérez, Roberto Fernández Mellado, Marta María García Clemente, Pere Casan Clara
The drug showed a favorable safety profile. From the total cohort of 69 patients, only 5 presented any drug-related adverse effects, with two cases leading to treatment withdrawal. Both patients reported arthralgias that did not remit with analgesic treatment. DREAM study (5) concluded that mepolizumab is a well-tolerated drug, with headaches and nasopharyngitis being the most frequent on-treatment adverse effects. In the SIRIUS study (14), the most frequent adverse effects were headaches (20% mepolizumab arm vs. 21% placebo arm) and nasopharyngitis (14% mepolizumab arm vs. 15% placebo arm). Also, 7 patients (4 mepolizumab arm vs. 3 placebo arm) had systemic reactions while 6 (4 mepolizumab arm vs. 2 placebo arm) had local reactions at the injection site. In the open label COSMOS study (7), only one patient presented serious adverse effects in relation with a hypersensitivity Type IV reaction and in the COSMEX (COSMOS extension study) (17) similar data was reported. No anaphylactic reactions after mepolizumab administration were observed in our patient cohort. Thus, literature reports along with the clinical results presented in this study suggest that mepolizumab is a drug that can be safely administered, and adverse reactions are overall few and slight.
Cluster headache: a single tertiary center study
Published in Neurological Research, 2022
Zeynep Tuncer Issı, Nurcan Akbulut, Vesile Öztürk
Comorbidity and living habits may also affect the duration and periods of attacks in CH. Smoking was present in the majority of patients (70–90%) [26,46]. Frequent attacks and long periods are more common in smoking CH patients than non-smokers; however, there was no improvement in CH patients after they quit smoking [46]. In Asian populations, alcohol use has not been sufficiently studied but the headaches triggered due to alcohol ranges from 51.3% to 75% [47,48]. Although the number of our patients who responded to smoking and alcohol use triggering headaches was low, 95% of those who responded were using cigarettes and 84.21% were using alcohol. In our study, additional chronic diseases of the patients were also recorded and the rate of comorbidity was found to be significantly higher in women. Again, arthralgia was also significantly higher in women. Hypertension was significantly higher in CCH patients when CCH and ECH were compared.